| Literature DB >> 22327218 |
Er-Chieh Cho1, Shunsheng Zheng, Shonagh Munro, Geng Liu, Simon M Carr, Jutta Moehlenbrink, Yi-Chien Lu, Lindsay Stimson, Omar Khan, Rebecca Konietzny, Joanna McGouran, Amanda S Coutts, Benedikt Kessler, David J Kerr, Nicholas B La Thangue.
Abstract
E2F transcription factors are implicated in diverse cellular functions. The founding member, E2F-1, is endowed with contradictory activities, being able to promote cell-cycle progression and induce apoptosis. However, the mechanisms that underlie the opposing outcomes of E2F-1 activation remain largely unknown. We show here that E2F-1 is directly methylated by PRMT5 (protein arginine methyltransferase 5), and that arginine methylation is responsible for regulating its biochemical and functional properties, which impacts on E2F-1-dependent growth control. Thus, depleting PRMT5 causes increased E2F-1 protein levels, which coincides with decreased growth rate and associated apoptosis. Arginine methylation influences E2F-1 protein stability, and the enhanced transcription of a variety of downstream target genes reflects increased E2F-1 DNA-binding activity. Importantly, E2F-1 is methylated in tumour cells, and a reduced level of methylation is evident under DNA damage conditions that allow E2F-1 stabilization and give rise to apoptosis. Significantly, in a subgroup of colorectal cancer, high levels of PRMT5 frequently coincide with low levels of E2F-1 and reflect a poor clinical outcome. Our results establish that arginine methylation regulates the biological activity of E2F-1 activity, and raise the possibility that arginine methylation contributes to tumourigenesis by influencing the E2F pathway.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22327218 PMCID: PMC3321197 DOI: 10.1038/emboj.2012.17
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598